NVS


Blackstone, Carlyle Mull $25B Bid to Acquire Novartis’ Sandoz — Report

This article was originally published on TipRanks.com.

Novartis Aims to Make Healthcare Affordable in Sub-Saharan African Region

Novartis (NVS) has launched a new innovation hub, Novartis Biome sub-Saharan Africa (SSA), to improve healthcare in the region by developing innovative business …

BeiGene’s Tislelizumab Gets Approval for First-Line Treatment of Advanced Non-Squamous NSCLC in China

China-based biopharmaceutical firm BeiGene (BGNE) has received approval for its anti-PD-1 antibody tislelizumab from the China National Medical Products Administration (NMPA) for the …

Novartis and Molecular Partners Begin EMPATHY Clinical Trial

Novartis Ag (NVS) announced that together with Molecular Partners it has begun clinical trial EMPATHY. The EMPATHY trial is a Phase 2 and …

Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy

Swiss drugmaker Novartis announced the acquisition of ocular gene therapy company Vedere Bio for a total consideration of $280 million. Under the terms …

Novartis’ Skin Cancer Drug Candidate Fails Late-Stage Trial Target

Novartis AG announced on Saturday that its investigational spartalizumab immunotherapy drug combined with Tafinlar and Mekinist therapies failed to meet its primary endpoint …

Novartis To Sell Covid-19 Drugs At Zero-Profit To Low-Income Countries

Novartis AG (NVS) announced Thursday that its Sandoz division will sell 15 generic drugs to treat COVID-19 symptoms at zero-profit to governments in …

Novartis Gets FDA Nod to Start Malaria Drug Trial For Coronavirus Cure

Swiss drugmaker Novartis AG (NVS) announced on Monday that it reached an agreement with U.S.

Novartis Buys U.S. Start-Up Amblyotech For Lazy Eye Treatment

Swiss drugmaker Novartis AG (NVS) said Monday it has acquired U.S.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts